Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

MarineMax, Inc.

HZO
Consumer Discretionary · Specialty Retail

MarineMax, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: the price moved +61.4% in a year while annual EPS moved −186.7% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is in a confirmed uptrend (19 weeks in). Underneath, the last four quarters read deteriorating, and −49% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.

Stage
Deteriorating
fundamental trajectory, 12 quarters
Price
$36.0
+61.4% 1Y
P/E
204.2×
of its own 4-year range
Revenue (Mar 26)
$0.5 B
−15.9% YoY
Profit (Mar 26)
$0.0 B
Operating margin
1.9%
−1.3 pp YoY
ROE
1%
FY25
ROIC
3.3%
vs WACC 8.0% → −4.7 pp
Cash conversion
−49%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

MarineMax, Inc. trades at $36.0, in a confirmed uptrend and 19 weeks into that stage. That is +23.8% against its own 200-day average. It sits at 88% of a 52-week range of $23 to $38. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 17 straight weeks.

Today the stock is in a confirmed uptrend — week 19 of stage 2. At $36.0 it trades +23.8% versus its 200-day average and sits at 88% of its 52-week range ($23–$38).

Aug 26: $36.0 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+23.8% versus the 200-day line, week 19 of stage 2
Price50-day avg200-day avg
S4S3S2$40.7$34.8$28.9$23.1$17.2$$36$29Jul 23Apr 24Jan 25Oct 25Aug 26
S4S3S2$40.7$34.8$28.9$23.1$17.2$$36$29Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +92% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 17 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

MarineMax, Inc. trades at 204.2× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 204.2× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 204.2× vs a null× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 3.6-year window; loss-period spikes above 19× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
against too little history to rank
P/EEPS (TTM) (quarterly)
20.3×$9.615.7×$7.211.1×$4.86.5×$2.41.9×$0.0×$10.11×$3Apr 22Feb 23Jan 24Dec 24Oct 25
20.3×$9.615.7×$7.211.1×$4.86.5×$2.41.9×$0.0×$10.11×$3Apr 22Jan 24Oct 25
PEG 0.45 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
1.0×0.9×0.7×0.6×0.4××0.45×Sep 21Sep 22Dec 23Mar 25Jun 26
1.0×0.9×0.7×0.6×0.4××0.45×Sep 21Dec 23Jun 26
P/E
204.2×
too little history to rank
PEG
3.32
derived from 3-year earnings growth

🚨 Why the multiple sits where it does: over the past year annual EPS moved −186.7% against a +61.4% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the −1.1%/yr price move, ~−34.9%/yr came from earnings growth and ~+33.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Deteriorating

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

MarineMax, Inc. reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −7.0% latest against +5.1% at its 12-quarter best), ROCE holding at 9.6%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue −4.9% in FY25, profit −175.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
13%51%8.5%−13%3.6%−77%−1.3%−140%−6.3%−204%%%−4.9%−175%FY21FY23FY25
13%51%8.5%−13%3.6%−77%−1.3%−140%−6.3%−204%%%−4.9%−175%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over
RevenueProfitEPS
6.1%5.5%2.6%−55%−1.0%−116%−4.5%−176%−8.0%−237%%%−7%−220%−220%Jun 23Sep 24Mar 26
6.1%5.5%2.6%−55%−1.0%−116%−4.5%−176%−8.0%−237%%%−7%−220%−220%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
19%16%13%10%7.6%%9.6%Jun 23Dec 23Sep 24Jun 25Mar 26
19%16%13%10%7.6%%9.6%Jun 23Sep 24Mar 26
Revenue growth
Flat
latest −7.0% · span −7.0% to +5.1%
Profit growth
Falling
latest −220.0% · span −220.0% to −16.7%
EPS growth
Falling
latest −220.0% · span −220.0% to −11.2%
ROCE
Stuck low
latest 9.6% · span 8.4%–17.8%

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue−4.9%+0.0%
Stock price+61.4%−1.1%−7.2%+5.9%
Revenue YoY (Mar 26)
−15.9%
latest quarter vs a year ago
Revenue 10y
2.9%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

50.8/100 — rank 10 of 28 in Specialty Retail · 58% evidence confidence

MarineMax, Inc. scores 50.8 out of 100 against the 28 companies it is compared with in Specialty Retail, ranking 10. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 19.1 + 9.3 + 8.5 + 13.9 = 50.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

MarineMax, Inc. reported $0.5 B of revenue in the Mar 26 quarter, −15.9% year on year. Over 4 years it has compounded at 2.9% a year. The last full year, FY25, came in at $2.3 B. The last four reported quarters add to $2.3 B.

FY25 revenue came in at $2.3 B (−4.9% on the year), capping 4 years at 2.9% compound. The latest quarter (Mar 26) printed $0.5 B, −15.9% year on year.

FY25 revenue $2.3 B (−4.9% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
2.9% a year over 4 years
RevenueYoY growth
2.613%2.08.5%1.33.6%0.7−1.3%0.0−6.3%$ B%$2B−4.9%FY21FY23FY25
2.613%2.08.5%1.33.6%0.7−1.3%0.0−6.3%$ B%$2B−4.9%FY21FY23FY25
Mar 26: $0.5 B (−15.9% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.811%0.64.0%0.4−3.3%0.2−11%0.0−18%$ B%$1B−15.9%Jun 23Sep 24Mar 26
0.811%0.64.0%0.4−3.3%0.2−11%0.0−18%$ B%$1B−15.9%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged −5.6% growth against the decade's 2.9% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −7.0% over the last 4 quarters against −3.6%/yr over the last 8 — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

MarineMax, Inc.'s operating margin is 1.9% in the Mar 26 quarter, −1.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.3% to 11.7%. The current quarter sits inside that band.

The latest quarter's operating margin is 1.9%, −1.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.3%–11.7%.

🚨 Why the margin moved: operating margin went −1.3 pp year on year while gross margin went +3.8 pp — the loss came mostly from the gross line: input costs and pricing.

FY25: 1.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 1.3–11.7% band over 5 years
operating marginYoY change (pp)
13%1.9%9.5%0.3%6.5%−1.3%3.5%−2.8%0.5%−4.4%%%1.3%−4%FY21FY23FY25
13%1.9%9.5%0.3%6.5%−1.3%3.5%−2.8%0.5%−4.4%%%1.3%−4%FY21FY23FY25
Mar 26: 1.9% operating margin (−1.3 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
11%6.2%6.4%0.8%1.8%−4.7%−2.8%−10%−7.4%−15%%%1.9%−1.3%Jun 23Sep 24Mar 26
11%6.2%6.4%0.8%1.8%−4.7%−2.8%−10%−7.4%−15%%%1.9%−1.3%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

MarineMax, Inc. earned $0.0 B of net profit in the Mar 26 quarter. The full FY25 year was a loss of $0.03 B. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 2 of the last 12 reported quarters were loss-making.

Mar 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $−0.0 B (−175.0%).

FY25 profit $−0.0 B (−175.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.2250%0.15−10%0.08−71%0.02−131%−0.05−192%$ B%$0B−175%FY21FY23FY25
0.2250%0.15−10%0.08−71%0.02−131%−0.05−192%$ B%$0B−175%FY21FY23FY25
Mar 26: $0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.05−5.7%0.02−76%0.00−146%−0.03−216%−0.06−286%$ B%$0B−150%Jun 23Sep 24Mar 26
0.05−5.7%0.02−76%0.00−146%−0.03−216%−0.06−286%$ B%$0B−150%Jun 23Sep 24Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years −49% of MarineMax, Inc.'s reported profit arrived as operating cash — a gap worth watching. In FY24 that was $−0.0 B of operating cash against $0.0 B of profit. After $0.1 B of capital spending, $−0.1 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY24: operating cash of $−0.0 B against reported profit of $0.0 B, leaving free cash of $−0.1 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is −49% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY24: CFO $−0.0 B vs profit $0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 4-year window, annual resolution.
−49% of 3-year profit arrived as cash
Operating cashNet profitFree cash
0.40.20.0−0.2−0.3$ B$0B$0B$−0BFY21FY22FY24
0.40.20.0−0.2−0.3$ B$0B$0B$−0BFY21FY22FY24
Jun 26: operating cash $0.1 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.11384%0.0480%−0.03−225%−0.10−530%−0.17−834%$ B%$0B−750%Jun 23Sep 24Jun 26
0.11384%0.0480%−0.03−225%−0.10−530%−0.17−834%$ B%$0B−750%Jun 23Sep 24Jun 26

🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

MarineMax, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY24: capex $0.1 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.080.060.040.020.00$ B$0BFY21FY22FY24
0.080.060.040.020.00$ B$0BFY21FY22FY24
Jun 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0220.100.0160.030.011−0.040.005−0.110.000−0.18$ B$ B$0B$0BJun 23Sep 24Jun 26
0.0220.100.0160.030.011−0.040.005−0.110.000−0.18$ B$ B$0B$0BJun 23Sep 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

MarineMax, Inc. earns a ROE of −3% in FY25. Return on invested capital clears the cost of that capital by −4.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −1.3% net margin on 0.94× asset turns.

FY25 ROE is −3%.

🚨 Why the return is what it is — the wiring (FY25): −1.3% net margin × 0.94× asset turns × 2.60× balance-sheet leverage ≈ −3.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 3.3% − 8.0% = a −4.7 pp spread. The 8.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE −3% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 8.0% cost of capital used on this page.
the full ladder
ROEROIC (annual)WACC
33%23%13%3.8%−5.9%%−3.2%1.4%FY21FY23FY25
33%23%13%3.8%−5.9%%−3.2%1.4%FY21FY23FY25
Jun 26: ROIC 1.3% (TTM) vs WACC 8.0% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
16%9.6%3.7%−2.2%−8.1%%1.3%0.5%Sep 23Dec 24Jun 26
16%9.6%3.7%−2.2%−8.1%%1.3%0.5%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

MarineMax, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

MarineMax, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

MarineMax, Inc. carries total debt of $1.1 B against shareholder equity of $1.0 B as of Jun 26, a debt-to-equity of 1.16. On the annual view that ratio went from 0.41 in FY20 to 1.32 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $1.1 B against shareholder equity of $1.0 B — a debt-to-equity of 1.16. On the annual view, debt-to-equity went from 0.41 (FY20) to 1.32 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $1.3 B at 1.32× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 6-year window.
Total debtDebt-to-equity
1.41.4×1.01.1×0.70.8×0.30.5×0.00.2×$ B×$1B1.32×FY20FY22FY25
1.41.4×1.01.1×0.70.8×0.30.5×0.00.2×$ B×$1B1.32×FY20FY22FY25
Jun 26: debt $1.1 B, debt-to-equity 1.16 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.41.38×1.11.32×0.71.26×0.41.20×0.01.14×$ B×$1B1.16×Sep 23Dec 24Jun 26
1.41.38×1.11.32×0.71.26×0.41.20×0.01.14×$ B×$1B1.16×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

12.1% of MarineMax, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 9.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 12.1% of the float is sold short, and at typical trading volumes it would take about 9.5 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
12.1%
of the tradable float
Days to cover
9.5
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

MarineMax, Inc.: the Z-score reads 1.83. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 1.83 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 1.83.

15 · Related companies · Specialty Retail
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Five Below, Inc.FIVE 70.6/100Favorable setup85% evidence ASLEEP 31.0/35 Revenue 25.8% · PAT 67.7% · OPM change 6.8 pp 95% evidence 14.0/25 ROCE 4% · OPM 12% 76% evidence 13.8/20 P/E 29.1× · PEG 0.73 65% evidence 11.8/20 RS sector 8.7% · RS bench 5.6% · 1Y 66.5%0 of 12 weeks ahead 100% evidence
Exact sum: 31 + 14 + 13.8 + 11.8 = 70.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Best Buy Co., Inc.BBY 69.6/100Favorable setup85% evidence BREAKING OUT 23.6/35 Revenue 1% · PAT 29.4% · OPM change 1.6 pp 95% evidence 13.1/25 ROCE 5.4% · OPM 4.1% 76% evidence 15.6/20 P/E 11.1× · PEG 0.35 65% evidence 17.3/20 RS sector 11.4% · RS bench 7.6% · 1Y 25.2%9 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 13.1 + 15.6 + 17.3 = 69.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Murphy USA Inc.MUSA 64.0/100Mixed-positive evidence81% evidence FADING 21.7/35 Revenue -1.2% · PAT 13.1% · OPM change 2.4 pp 83% evidence 13.5/25 ROCE 5.5% · OPM 4.3% 76% evidence 14.2/20 P/E 17.1× · PEG 0.78 65% evidence 14.6/20 RS sector 19% · RS bench 15.9% · 1Y 56%7 of 12 weeks ahead 100% evidence
Exact sum: 21.7 + 13.5 + 14.2 + 14.6 = 64 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Casey's General Stores, Inc.CASY 59.8/100Mixed-positive evidence85% evidence ASLEEP 24.8/35 Revenue 10.2% · PAT 30.8% · OPM change 1.2 pp 95% evidence 12.4/25 ROCE 3.2% · OPM 5.1% 76% evidence 10.0/20 P/E 42.9× · PEG 1.39 65% evidence 12.6/20 RS sector 18.1% · RS bench 15.1% · 1Y 63.9%4 of 12 weeks ahead 100% evidence
Exact sum: 24.8 + 12.4 + 10 + 12.6 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Williams-Sonoma, Inc.WSM 55.4/100Mixed-positive evidence85% evidence BREAKING OUT 13.7/35 Revenue 1.3% · PAT -0.6% · OPM change -0.6 pp 95% evidence 16.4/25 ROCE 8.7% · OPM 16.2% 76% evidence 8.0/20 P/E 20.2× · PEG 2.1 65% evidence 17.3/20 RS sector 16.1% · RS bench 12.2% · 1Y 24.8%9 of 12 weeks ahead 100% evidence
Exact sum: 13.7 + 16.4 + 8 + 17.3 = 55.4 · Decision use: Price leads the evidence: RS versus the benchmark is 12.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
6Bath & Body Works, Inc.BBWI 55.1/100Mixed-positive evidence85% evidence TURNING 14.7/35 Revenue -1.4% · PAT -10.9% · OPM change 2.1 pp 95% evidence 15.2/25 ROCE 6.4% · OPM 16.8% 76% evidence 16.5/20 P/E 5.4× · PEG 0.24 65% evidence 8.7/20 RS sector -10.3% · RS bench -14.1% · 1Y -26.1%1 of 12 weeks ahead 100% evidence
Exact sum: 14.7 + 15.2 + 16.5 + 8.7 = 55.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
7Build-A-Bear Workshop, Inc.BBW 53.3/100Mixed-positive evidence79% evidence BASING 17.8/35 Revenue 3.5% · PAT -3.6% · OPM change 3.9 pp 95% evidence 17.5/25 ROCE 9.9% · OPM 19% 76% evidence 14.6/20 P/E 8.4× · PEG 0.79 65% evidence 3.4/20 RS sector -34.1% · RS bench -37.1% · 1Y -30.6%0 of 12 weeks ahead 70% evidence
Exact sum: 17.8 + 17.5 + 14.6 + 3.4 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Sally Beauty Holdings, Inc.SBH 51.8/100Mixed-positive evidence75% evidence TURNING 14.2/35 Revenue 0.8% · PAT -0.5% · OPM change 0.1 pp 83% evidence 12.9/25 ROCE 3.2% · OPM 8% 76% evidence 11.5/20 P/E 7.7× · PEG 1.5 65% evidence 13.2/20 RS sector 5% · RS bench 1.3% · 1Y 41.8%1 of 12 weeks ahead 70% evidence
Exact sum: 14.2 + 12.9 + 11.5 + 13.2 = 51.8 · Decision use: Price leads the evidence: RS versus the benchmark is 1.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
9Winmark CorporationWINA 51.8/100Thin evidence · provisional52% evidence BASING 16.8/35 Revenue — · PAT — · OPM change -2.7 pp 45% evidence 21.4/25 ROCE 38.3% · OPM 59.3% 76% evidence 9.5/20 P/E 37.9× · PEG — 15% evidence 4.1/20 RS sector -21.8% · RS bench -24.8% · 1Y -8.4%0 of 12 weeks ahead 70% evidence
Exact sum: 16.8 + 21.4 + 9.5 + 4.1 = 51.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10MarineMax, Inc.this pageHZO 50.8/100Thin evidence · provisional58% evidence FADING 19.1/35 Revenue — · PAT — · OPM change -1.5 pp 45% evidence 9.3/25 ROCE 2.5% · OPM 2.1% 76% evidence 8.5/20 P/E 261.6× · PEG — 15% evidence 13.9/20 RS sector 16.6% · RS bench 13.2% · 1Y 60.1%10 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 9.3 + 8.5 + 13.9 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11RHRH 50.3/100Mixed-positive evidence77% evidence BREAKING OUT 13.3/35 Revenue 4.8% · PAT 23.3% · OPM change -2.6 pp 71% evidence 9.1/25 ROCE 0.9% · OPM 4.3% 76% evidence 14.2/20 P/E 25.1× · PEG 0.53 65% evidence 13.7/20 RS sector 1.1% · RS bench -3.3% · 1Y -12.5%8 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 9.1 + 14.2 + 13.7 = 50.3 · Decision use: Price leads the evidence: RS versus the benchmark is -3.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
12National Vision Holdings, Inc.EYE 48.1/100Thin evidence · provisional52% evidence BASING 21.5/35 Revenue — · PAT — · OPM change 4.9 pp 45% evidence 11.1/25 ROCE 2.9% · OPM 8.3% 76% evidence 9.3/20 P/E 41.6× · PEG — 15% evidence 6.2/20 RS sector -11.8% · RS bench -15.1% · 1Y 2.1%0 of 12 weeks ahead 70% evidence
Exact sum: 21.5 + 11.1 + 9.3 + 6.2 = 48.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13GameStop Corp.GME 47.4/100Mixed-negative evidence75% evidence ASLEEP 25.3/35 Revenue 1.6% · PAT 100% · OPM change 18.7 pp 95% evidence 10.1/25 ROCE 1.7% · OPM 17.2% 76% evidence 10.3/20 P/E 20.1× · PEG — 15% evidence 1.7/20 RS sector -21.7% · RS bench -24.4% · 1Y -13.7%0 of 12 weeks ahead 100% evidence
Exact sum: 25.3 + 10.1 + 10.3 + 1.7 = 47.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -21.7% and the one-year return is -13.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
14Barnes & Noble Education, Inc.BNED 46.7/100Thin evidence · provisional52% evidence LEADER 14.7/35 Revenue — · PAT — · OPM change 1.8 pp 45% evidence 5.1/25 ROCE -3.6% · OPM 3.2% 76% evidence 10.1/20 P/E 21× · PEG — 15% evidence 16.8/20 RS sector 25% · RS bench 21.2% · 1Y 48.3%12 of 12 weeks ahead 70% evidence
Exact sum: 14.7 + 5.1 + 10.1 + 16.8 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15Tractor Supply CompanyTSCO 44.4/100Thin evidence · provisional58% evidence TURNING 13.9/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence 14.2/25 ROCE 5.6% · OPM 6.5% 76% evidence 10.7/20 P/E 16.3× · PEG — 15% evidence 5.6/20 RS sector -34% · RS bench -36.9% · 1Y -44.1%0 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 14.2 + 10.7 + 5.6 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Arko Corp.ARKO 43.3/100Mixed-negative evidence68% evidence FADING 15.9/35 Revenue -10.6% · PAT 100% · OPM change 1.2 pp 62% evidence 6.7/25 ROCE 0.3% · OPM 0.6% 76% evidence 4.6/20 P/E 29.3× · PEG 3.94 65% evidence 16.1/20 RS sector 18.9% · RS bench 15.9% · 1Y 53.8%11 of 12 weeks ahead 70% evidence
Exact sum: 15.9 + 6.7 + 4.6 + 16.1 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 15.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
17Arhaus, Inc.ARHS 42.7/100Mixed-negative evidence75% evidence TURNING 16.2/35 Revenue 7.4% · PAT 10.3% · OPM change -1 pp 83% evidence 8.3/25 ROCE 0.2% · OPM 0.7% 76% evidence 13.1/20 P/E 14.4× · PEG 0.99 65% evidence 5.1/20 RS sector -15.4% · RS bench -19% · 1Y -26.2%3 of 12 weeks ahead 70% evidence
Exact sum: 16.2 + 8.3 + 13.1 + 5.1 = 42.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Olaplex Holdings, Inc.OLPX 42.4/100Thin evidence · provisional58% evidence 10.7/35 Revenue 0.9% · PAT -225% · OPM change -13.8 pp 62% evidence 5.8/25 ROCE -0.3% · OPM -5.1% 76% evidence 9.0/20 P/E 63.5× · PEG — 15% evidence 16.9/20 RS sector 28.6% · RS bench 20.4% · 1Y 43.8%5 of 8 weeks ahead to 2026-07-10 70% evidence
Exact sum: 10.7 + 5.8 + 9 + 16.9 = 42.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
191-800-FLOWERS.COM, Inc.FLWS 40.0/100Thin evidence · provisional58% evidence ASLEEP 20.5/35 Revenue -9.5% · PAT — · OPM change 26.1 pp 62% evidence 3.3/25 ROCE -17.8% · OPM -32.3% 76% evidence 8.6/20 P/E 191.2× · PEG — 15% evidence 7.6/20 RS sector -5.6% · RS bench -9.2% · 1Y -25.5%6 of 12 weeks ahead 70% evidence
Exact sum: 20.5 + 3.3 + 8.6 + 7.6 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Academy Sports and Outdoors, Inc.ASO 39.9/100Mixed-negative evidence85% evidence BASING 14.7/35 Revenue 3.8% · PAT -1.3% · OPM change 0.1 pp 95% evidence 11.3/25 ROCE 1.8% · OPM 5.2% 76% evidence 10.3/20 P/E 9.5× · PEG 1.73 65% evidence 3.6/20 RS sector -13.5% · RS bench -16.5% · 1Y -1.9%0 of 12 weeks ahead 100% evidence
Exact sum: 14.7 + 11.3 + 10.3 + 3.6 = 39.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Savers Value Village, Inc.SVV 38.5/100Thin evidence · provisional52% evidence BREAKING OUT 11.5/35 Revenue — · PAT — · OPM change -5.1 pp 45% evidence 7.3/25 ROCE 0.7% · OPM 3.1% 76% evidence 9.1/20 P/E 53.6× · PEG — 15% evidence 10.6/20 RS sector 1.1% · RS bench -3.1% · 1Y -3.8%8 of 12 weeks ahead 70% evidence
Exact sum: 11.5 + 7.3 + 9.1 + 10.6 = 38.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Ulta Beauty, Inc.ULTA 38.2/100Mixed-negative evidence85% evidence BASING 13.9/35 Revenue 11.3% · PAT -0.1% · OPM change 0.1 pp 95% evidence 10.4/25 ROCE 0% · OPM 14.2% 76% evidence 7.5/20 P/E 19.9× · PEG 2.3 65% evidence 6.4/20 RS sector -8.3% · RS bench -11.6% · 1Y 9.2%0 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 10.4 + 7.5 + 6.4 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23OneWater Marine Inc.ONEW 38.1/100Thin evidence · provisional58% evidence TURNING 12.0/35 Revenue 3.1% · PAT — · OPM change -1.7 pp 62% evidence 7.2/25 ROCE 0.9% · OPM 1.7% 76% evidence 11.0/20 P/E 10.4× · PEG — 15% evidence 7.9/20 RS sector -5.3% · RS bench -9.2% · 1Y -16%6 of 12 weeks ahead 70% evidence
Exact sum: 12 + 7.2 + 11 + 7.9 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24EVgo, Inc.EVGO 37.5/100Mixed-negative evidence61% evidence BASING 21.0/35 Revenue 50.4% · PAT — · OPM change 11.2 pp 62% evidence 3.5/25 ROCE -4.7% · OPM -33.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 3.0/20 RS sector -42.9% · RS bench -45.7% · 1Y -50%0 of 12 weeks ahead 100% evidence
Exact sum: 21 + 3.5 + 10 + 3 = 37.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Petco Health and Wellness Company, Inc.WOOF 36.9/100Mixed-negative evidence67% evidence TURNING 13.8/35 Revenue -1.9% · PAT — · OPM change 0.5 pp 71% evidence 6.1/25 ROCE 0.6% · OPM 1.6% 76% evidence 8.7/20 P/E 144× · PEG — 15% evidence 8.3/20 RS sector -7.9% · RS bench -11.4% · 1Y -6.6%2 of 12 weeks ahead 100% evidence
Exact sum: 13.8 + 6.1 + 8.7 + 8.3 = 36.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26DICK'S Sporting Goods, Inc.DKS 35.0/100Mixed-negative evidence85% evidence ASLEEP 12.0/35 Revenue 41.2% · PAT -21.7% · OPM change -2.8 pp 95% evidence 13.8/25 ROCE 4.4% · OPM 8.7% 76% evidence 5.6/20 P/E 21.4× · PEG 2.85 65% evidence 3.6/20 RS sector -13.4% · RS bench -16.2% · 1Y -5%3 of 12 weeks ahead 100% evidence
Exact sum: 12 + 13.8 + 5.6 + 3.6 = 35 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27Bed Bath & Beyond, Inc.BBBY 31.4/100Thin evidence · provisional58% evidence TURNING 14.2/35 Revenue -14.8% · PAT — · OPM change 2.7 pp 62% evidence 3.5/25 ROCE -9.8% · OPM -7.3% 76% evidence 8.9/20 P/E 121.8× · PEG — 15% evidence 4.8/20 RS sector -19.9% · RS bench -23.5% · 1Y -29.9%5 of 12 weeks ahead 70% evidence
Exact sum: 14.2 + 3.5 + 8.9 + 4.8 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Bob's Discount Furniture, Inc.BOBS 48.3/100Thin evidence · provisional28% evidence BREAKING OUT 17.1/35 Revenue — · PAT — · OPM change -0.3 pp 26% evidence 11.2/25 ROCE 2.7% · OPM 3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence
Exact sum: 17.1 + 11.2 + 10 + 10 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is MarineMax, Inc.'s stock price today?

MarineMax, Inc. trades at $36.0, +61.4% over the past year. The company is valued at $1.0 B. The stock sits at 88% of its 52-week range of $23–$38, +23.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 19 weeks in. — as of 5 August 2026.

What were MarineMax, Inc.'s latest quarterly results?

MarineMax, Inc. reported revenue of $0.5 B and net profit of $0.0 B for the Mar 26 quarter. The operating margin was 1.9%, 1.3 pp lower than a year earlier. — as of 5 August 2026.

What is MarineMax, Inc.'s revenue?

MarineMax, Inc. reported revenue of $0.5 B in the Mar 26 quarter, −15.9% year on year. For the full FY25 fiscal year, revenue was $2.3 B (−4.9%). Over the last 4 years revenue compounded at 2.9% a year. — as of 5 August 2026.

What is MarineMax, Inc.'s profit?

MarineMax, Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.0 B. The operating margin ran 1.9% in the latest quarter. — as of 5 August 2026.

What is MarineMax, Inc.'s market cap?

MarineMax, Inc.'s market capitalisation is $1.0 B at a stock price of $36.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does MarineMax, Inc. pay a dividend?

No — MarineMax, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

How is MarineMax, Inc. performing?

MarineMax, Inc. is in a confirmed uptrend, 19 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 17 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is MarineMax, Inc. in?

Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −7.0% latest against +5.1% at its 12-quarter best), ROCE holding at 9.6%. The read comes from the last 12 quarters of growth (revenue growth −7.0% latest, profit growth −220.0% latest, eps growth −220.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is MarineMax, Inc. in an uptrend?

Yes — the price is in a confirmed uptrend (week 19 of stage 2), trading +23.8% versus its 200-day average and at 88% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is MarineMax, Inc. beating the market?

On recent form, yes — MarineMax, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 17 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +92% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will MarineMax, Inc.'s stock price go up?

This page publishes no price forecast for MarineMax, Inc. What it measures instead: the stock price is $36.0, the price is in a confirmed uptrend 19 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against MarineMax, Inc.?

Yes — short interest is 12.1% of MarineMax, Inc.'s tradable float, about 9.5 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does MarineMax, Inc. have too much debt?

It carries real leverage — MarineMax, Inc.'s debt-to-equity is 1.15. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is MarineMax, Inc.'s capex?

MarineMax, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY24 alone that was $0.1 B. — as of 5 August 2026.

What is MarineMax, Inc.'s cash flow?

MarineMax, Inc. generated $−0.0 B of operating cash flow in FY24 and $−0.1 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran behind profit. — as of 5 August 2026.

Is MarineMax, Inc.'s profit real cash?

Not fully — over the last 3 fiscal years, −49% of MarineMax, Inc.'s reported profit arrived as operating cash. In FY24, operating cash was $−0.0 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is MarineMax, Inc.?

On the balance sheet, the Z-score reads 1.83 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.

Where is MarineMax, Inc. in its business cycle?

MarineMax, Inc.'s FY25 operating margin was 1.3%, against a 5-year band of 1.3%–11.7%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 1.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the MarineMax, Inc. story?

The sharpest disagreement: the price moved +61.4% in a year while annual EPS moved −186.7% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is MarineMax, Inc. a stock worth studying right now?

This is not investment advice. The machine read: MarineMax, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI